<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272480</url>
  </required_header>
  <id_info>
    <org_study_id>BRIDGE1.0</org_study_id>
    <nct_id>NCT00272480</nct_id>
  </id_info>
  <brief_title>Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial</brief_title>
  <official_title>Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <brief_summary>
    <textblock>
      To determine whether the use of two antiviral agents in combination will be better than
      placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine
      in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by
      6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints:
      virological and immunological
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date>November 2001</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Timed walk</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain score</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary frequency</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Bowel function</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disability scale</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of proliferation</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>HTLV-I-associated Myelopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine/lamivudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HTLV-I-associated myelopathy -

        Exclusion Criteria:

        prior exposure to zidovudine or lamvudine on disease modifying therapy under age 16
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham P Taylor, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Taylor GP et al The Bridge Study - A double-blind, placebo controlled trial of zidovudine plus lamivudine for the treatment of patients with HTLV-I-associated myelopathy AIDS Research and Human Retroviruses 2003;19 (suppl 1) #O23</citation>
  </reference>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2006</study_first_submitted>
  <study_first_submitted_qc>January 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2006</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <keyword>HAM/TSP</keyword>
  <keyword>HTLV-I-associated myelopathy</keyword>
  <keyword>zidovudine</keyword>
  <keyword>lamivudine</keyword>
  <keyword>antiretroviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

